Phenobarbital specific antisera and radioimmunoassay

Application of TDM, pharmacogenomics and biomarkers for neurological disease pharmacotherapy: focus on antiepileptic drugs

Anticonvulsants, or antiepileptic drugs (AEDs), are a vital tool in the therapeutic management of epilepsy patients. However, many AEDs are commonly used in the management of nonepileptic conditions, such as chronic pain, migraine headaches and psychiatric disorders. It is well documented that serum drug levels are an important data tool for the management of patients taking these drugs. As we move toward the personalized optimization of pharmacotherapy, drug level data will not be sufficient. This article will review tools for therapeutic drug management of AEDs including pharmacogenetics and biomarkers, in addition to traditional serum drug levels.

Nicotine antibodies: comparison of ligand specificities of antibodies produced against two nicotine conjugates

Conjugates between bovine serum albumin and (R,S)-2-aminonicotine were produced, and these conjugates were employed in rabbits and goats for the production of nicotine antibodies. In the assay of nicotine, an 125I-tyrosine methyl ester derivative of (R,S)-6-aminonicotine was employed as radioligand. The antibody-bound derivative was separated from the free derivative by charcoal adsorption (0.5% charcoal, 0.1% dextran T-70, 0.1% bovine serum albumin pH 7.3). Among the twenty five nicotine derivatives and metabolites examined, (R,S)-6-aminonicotine gave the highest cross-reaction. Cross-reaction with cotinine, a major mammalian metabolite of nicotine, was less than 0.1% for both the rabbit-derived and goat-derived antisera. Cross-reaction by other metabolites, such as (S)-nicotine-N'-oxide, (S)-nornicotine, and N-methylpyrrolidine was less than 1%. The antibodies produced were thus highly specific to nicotine. The radioimmunoassay for nicotine showed a maximum sensitivity of 10 ng/ml in 50-microliter plasma samples for both antisera. After the smoking of a single cigarette (1.2 mg nicotine content in mainstream) the peak of blood plasma level of nicotine in the subjects varied from 20--104 ng/ml, and high levels of nicotine were not necessarily found in heavy smokers.

Automated radioimmunoassay of nicotine

We have developed an automated nonequilibrium procedure for the radioimmunoassay of nicotine. The use of a unique iodinated nicotine derivative in this procedure gave a sensitivity of 10 micrograms/l for nicotine with a between-run precision of 7.4% and within-run precision of 6.0%. Nicotine levels of 60 to 67 micrograms/ml were found in subjects 15 min after smoking one standard cigarette. The technique herein reported is a very rapid, and sensitive radioimmunoassay for nicotine and facilitates the determination of nicotine in smoking subjects during the actual process of smoking.

Determination of phenobarbital by radioimmunoassay

A radioimmunoassay for phenobarbital has been studied. Antiphenobarbital antisera were obtained by repeated immunization of rabbits with p-succinamidophenobarbital conjugated to bovine serum albumin. Less than 0.2 pmol of phenobarbital could be measured by this procedure. The specificity of the antibodies was directed to substituents on the nitrogen atoms of the barbituric ring as well as to substituents at the carbon 5-position of the ring.

Determination of drugs of abuse in body fluids by radioimmunoassay

Only recently has radioimmunoassay been used for the detection of drugs of abuse in body fluids. The radioimmunoassay method is rapid, sensitive, specific, and can be performed with a minimum of sample, while conventional assay methods are time-consuming, relatively insensitive, and require a larger sample volume. Performance of individual radioimmunoassays is identical, and requires about one hour to complete. The radioimmunoassays which have been developed for measurement of drugs of abuse in humans are reviewed in this paper. These new techniques are of importance in individual and/or emergency testing, in screening, and in further research into the effect of these drugs on the functions of the human body.